Clinical Trial Update: Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial sponsored by the University of Turin evaluated two anti-CD20 regimens for fibrillary glomerulonephritis and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrillary Glomerulonephritis

Snippet

Sponsor: University of Turin, Italy | Conditions: Fibrillary Glomerulonephritis | Phase 4 | Status: COMPLETED